ADC Therapeutics SA (ADCT) Cash Flow Statement
ADC Therapeutics SA (ADCT) generated -$102.3M of operating cash flow over the twelve months to 2026-06-30, spent $32000 on capital expenditure and had free cash flow of -$102.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ADCTADC Therapeutics SAFollow ADCT — free
—
Price chart with a free account
- Market cap
- 183.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -118.7 | -123.8 | -141.2 | -102.3 | |
| Capital expenditure | 3.2 | 0.9 | 0.3 | -0.0 | |
| Free cash flow | -121.9 | -124.7 | -141.4 | -102.3 | |
| Stock-based compensation | 13.5 | 6.6 | 6.9 | — |
USD millions · SEC XBRL
ADC Therapeutics SA — questions
- What is ADC Therapeutics SA's operating cash flow?
- -$102.3M over the twelve months to 2026-06-30.
- How much does ADC Therapeutics SA spend on capital expenditure?
- $32000 over the twelve months to 2026-06-30.
- What is ADC Therapeutics SA's free cash flow?
- -$102.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from ADC Therapeutics SA's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.